Skip to content

Mandibular Furcation III Regeneration (FURC-III-REGEN)

Biphasic Calcium Phosphate and a Collagen Membrane or Biphasic Calcium Phosphate and Enamel Matrix Proteins, in the Regenerative Treatment of Furcation Grade III Defects

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04059458
Acronym
FURC-III-REGEN
Enrollment
5
Registered
2019-08-16
Start date
2019-10-15
Completion date
2023-11-27
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Furcation Defects, Periodontal Diseases

Brief summary

Teeth with furcation grade III defects will be treated with open flap debridement and regenerative therapy with biphasic calcium phosphate combined with either enamel matrix proteins or a collagen membrane.

Interventions

Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.

Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.

Sponsors

University of Oslo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject must be ≥ 20 years * Subject must have periodontal disease as determined by the World Workshop 2017 criteria * Subjects must be undergoing periodontal treatment or follow-up and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade II with PPD \>4 mm, and the furcation fornix must be below a tangential line from the distal to mesial interproximal crestal bone level * Competent to give consent

Exclusion criteria

The following must not be present at the time of enrolment; * Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment * Present or past use of bisphosphonate treatment * Pregnant or nursing subjects * Patients classified as \> class 2 according to the ASA (American Society of Anesthesiologists) physical status classification * Previous surgical therapy of included furcation defects * Inability to comprehend and respond to the quality of life questionnaire * Dental restorations or prosthesis involving the furcation area * Root fractures or suspected infractions * Caries lesions in the furcation area * No systemic antibiotic treatment within 3 months prior to intervention

Design outcomes

Primary

MeasureTime frameDescription
Change of furcation grade level12 months after treatmentProportion of sites demonstrating improvement in furcation grade level as measured with Nabers probe

Secondary

MeasureTime frameDescription
Changes in patient-reported quality of life (QoL)Preoperatively compared to 24 months after treatmentTo assess QoL changes related to mouth and teeth prior to therapy to after therapy by the use of The Oral Impacts on Daily Performance (OIDP) instrument. Each question is assessed by a 5-point scale; (1) never affected, (2) less than once a month, (3) once or twice a month, (4) once or twice a week; and (5) every or nearly every day. The higher number represents more severe impact on quality of life; e.g. worse outcome. Each item will be dichotomised yielding the categories (A) affected; including scale categories (2)-(5), and (B) unaffected, including category (1).
Changes in defect morphology assessed by CBCT24 months after treatmentCone beam computed tomography will be acquired at baseline, 2 weeks postoperatively and 24 months postoperatively. This outcome measures quantitative morphologic changes in the furcation defects at 24 months
Changes in pocket probing depth12 months after treatmentChanges in pocket probing depth will be measured with a probe
Changes in PPD12 months after treatmentChanges in pocket probing depth will be measured with a probe
Radiographic changes12 months after treatmentStandardized intraoral bitewing radiographs will be obtained and compared to baseline radiographs
Pain following surgeryUp to 1 week postoperativelyPain sensation one week posteoperatively will be recorded on a visual analog scale from 0-10. 0 means no pain sensation, whereas 10 means highest pain imagineable.
Caries assessment24 monthsCaries in furcation defect assessed with an explorer will be recorded as (Y/N)

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026